[
  {
    "ts": null,
    "headline": "Why Organon Is A Top Pick For Income Investors",
    "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
    "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742252303,
      "headline": "Why Organon Is A Top Pick For Income Investors",
      "id": 133211092,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1472143072/image_1472143072.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "In mid-Feb., Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for income-oriented investors.",
      "url": "https://finnhub.io/api/news?id=697fea97f771736843602e4ccd567ee09566458d477be611dbdde99159b46b96"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results",
    "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing serious health conditions. Despite these promising developments, the company's shares saw a 1% decline over the past month, reflecting broader market challenges. The Nasdaq Composite, where Regeneron is listed, has been impacted by ongoing economic uncertainties and political factors, leading to...",
    "url": "https://finnhub.io/api/news?id=8df4fee9807db2d1f8a2597be88cf6df9416d1858d2f906d90de07d3f850bd61",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742232152,
      "headline": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results",
      "id": 133325928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing serious health conditions. Despite these promising developments, the company's shares saw a 1% decline over the past month, reflecting broader market challenges. The Nasdaq Composite, where Regeneron is listed, has been impacted by ongoing economic uncertainties and political factors, leading to...",
      "url": "https://finnhub.io/api/news?id=8df4fee9807db2d1f8a2597be88cf6df9416d1858d2f906d90de07d3f850bd61"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=3af2d20cb09a68f5f9d3ced99d5757330995fa501f4016f3babd9a6cb069c750",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742229720,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 133222587,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=3af2d20cb09a68f5f9d3ced99d5757330995fa501f4016f3babd9a6cb069c750"
    }
  },
  {
    "ts": null,
    "headline": "2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off",
    "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
    "url": "https://finnhub.io/api/news?id=87f7b261071dbfce06fedf6dcbab72f105692c608bbbd39d42f1bfcfc6874589",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742216482,
      "headline": "2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off",
      "id": 133325845,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.",
      "url": "https://finnhub.io/api/news?id=87f7b261071dbfce06fedf6dcbab72f105692c608bbbd39d42f1bfcfc6874589"
    }
  }
]